Alison J. Moskowitz, MD
Lymphoma Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Cutaneous T Cell Lymphoma
Request an Appointment
About Me
I am a hematologist-oncologist who cares for people with lymphoma, including non-Hodgkin lymphoma. I have a particular focus on Hodgkin lymphoma, systemic T cell lymphoma, and cutaneous T cell lymphoma (a rare type of skin lymphoma).
Read more
I have been at Memorial Sloan Kettering for more than 11 years. I am part of a team of lymphoma experts who are committed not only to providing world-class care but also to finding newer and better ways to treat these diseases.
Hodgkin lymphoma is a relatively rare disease, but because of treatment advances, we can often cure it. By incorporating newer drugs into our current standard treatments, we can study how patients tolerate their treatment for Hodgkin lymphoma and can lessen the drugs’ long-term negative effects on the body.
T cell lymphoma is rare and can be challenging to treat. Our clinical trials in T cell lymphoma are testing targeted therapies and immunotherapies aimed at improving our ability to control the disease and patients’ quality of life — as well as the chance of a cure.
When I see patients for the first time, my goal is that they leave the appointment with a clear understanding of their diagnosis and treatment options, as well as the many resources available at MSK to help them cope with their treatment. I am fortunate to work with a team of nurses, social workers, and clinical assistants who create a comforting and supportive environment for our patients. While I understand that it is very scary for people to be told they have cancer, it is important to me that I help make the experience less scary and work with my patients so they feel as well as possible.
A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.
My Specialties
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Cutaneous T Cell Lymphoma
Education
- MD, Albert Einstein College of Medicine
Residencies
- Internal Medicine - Columbia University Medical Center
Fellowships
- Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
Board Certifications
- Medical Oncology
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Moskowitz sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Moskowitz
- A Phase 1 Study of SGN-35T in People with Lymphoma
- A Phase 2 Study of AFM13 Plus AB-101 To Treat Hodgkin Lymphoma and Peripheral T-Cell Lymphoma
- A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia
- A Phase 3 Study of Brentuximab Vedotin in People With Hodgkin Lymphoma
Read more
- A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy plus Gemcitabine to Treat Advanced Mycosis Fungoides or Sézary Syndrome
- A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
- A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
- Clinical Trials Co-Investigated by Dr. Moskowitz
- A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- A Phase 2 Study of BV-AVD in People With Newly Diagnosed Bulky Hodgkin Lymphoma
- A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
- A Phase I Study of N-Acetylcysteine in People Receiving CAR T-Cell Therapy for Lymphoma
- A Phase III Study of Nivolumab in Combination with Chemo-Immunotherapy to Treat Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Moskowitz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alison J. Moskowitz discloses the following relationships and financial interests:
-
Affimed
Professional Services and Activities (Uncompensated) -
AstraZeneca
Professional Services and Activities (Uncompensated) -
Bristol-Myers Squibb
Professional Services and Activities -
Miami Cancer Institute
Professional Services and Activities
-
New York Oncology Hematology
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
Seagen
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.